2-Amino-3,5-dibromobenzaldehyde is supplied as a pharmaceutical-grade active pharmaceutical ingredient under the manufacturer-specific model code ALD-2A35DBB-PG. The molecular formula is C₇H₅Br₂NO; the molecular weight is 278.93 g/mol; the CAS registry number is 50910-55-9. The molecule carries a primary aromatic amino group at position 2, a benzaldehyde carbonyl at position 1, and bromine substituents at positions 3 and 5. This substitution pattern gives a higher molecular weight, stronger lipophilicity, and greater ring deactivation than the mono-brominated and non-halogenated amino benzaldehydes. Two grades are available: a solid oral grade for tablet, capsule, and granule processing and an injectable grade with reduced endotoxin burden, microbial load, and sub-visible particulate matter. Both grades require the same chemical purity but differ in route-specific release tests.

The powder is reported to melt at 138–142 °C; because no monograph for this substituted benzaldehyde appears in USP, Ph. Eur., or JP, the release specification is based on the ICH Q6A decision tree for new drug substances and the batch certificate remains the governing document. The solid oral grade is typically milled to a D₉₀ of ≤ 75 µm for direct compression and dry blending. The injectable grade is controlled to a finer particle distribution and to the bacterial endotoxin limit calculated from the maximum parenteral dose.

What Limits Solid Oral Processability When the Aldehyde and Aromatic Amino Group Coexist?

The main processing constraint is the reactivity of the aldehyde carbonyl with primary amino groups, including those present on the molecule itself and on excipients. The intramolecular amino-aldehyde arrangement can generate chromophoric Schiff-base species if the material is stored above 40 °C or in the presence of strong acid. In wet granulation with water, the aldehyde can be partially hydrated to a geminal diol, which can appear as an early-eluting HPLC peak and reduce the assay. Aqueous granulation is therefore carried out at pH below 6 and with a drying endpoint not exceeding 2.0% loss on drying. Isothermal microcalorimetry and differential scanning calorimetry at 10 K/min under nitrogen are used to detect incompatible excipient transitions before stability batches are placed. The product should not be combined with ammonia-neutralized disintegrants, tromethamine, or primary amine binders because these excipients can form Schiff-base adducts.

For tablet and capsule intermediates, the powder is first passed through a 500 µm cone mill or oscillating granulator. The milled lot is blended in a bin blender at 60–70% vessel fill for 20–30 minutes with a ductile filler such as microcrystalline cellulose and a disintegrant such as crospovidone. Because brominated crystals can show high elastic recovery, tablets produced without a binder may exhibit edge chipping and low tensile strength. An instrumented rotary press with precompression is used to derive the Heckel yield pressure; the compression profile is then locked to maintain tablet hardness within 4–8 kp for immediate-release tablets and disintegration per USP <701> within 15 minutes in 0.1 M HCl. Capsule filling uses a tamping or dosator setting adjusted to tapped density, and blend uniformity is monitored by near-infrared spectroscopy and by assay using USP <621>.

Jet milling of the unmicronized product at 0.7–1.2 MPa grinding air pressure reduces the D₉₀ from approximately 150–250 µm to 20–75 µm. The milled powder acquires electrostatic charge and requires handling below 40% RH to prevent agglomeration. If material is exposed to RH > 60%, pre-drying in a vacuum oven at 40–45 °C for 12–24 hours is required before dispensing. These processing parameters are development screening values and are not release limits; published data for this specific configuration in high-volume production is limited.

Injectable-Grade Control of Endotoxin, Particulate Matter, and Aldehyde-Reactive Excipients

Injectable formulations require route-specific release testing beyond solid oral controls. Because the product contains an aldehyde group, the formulation should avoid bisulfite and sulfite antioxidants, which form aldehyde-bisulfite addition products and can deplete the active form. Primary amino buffers such as tromethamine should be excluded for the same reason. Solubility in water is limited; parenteral development typically uses a co-solvent system or pH adjustment below the pKa of the aromatic amino group to increase ionization and dissolution. The pH of the prepared solution is selected from forced degradation data generated under ICH Q1A/R2 and photostability data generated under ICH Q1B, because brominated aromatic compounds can undergo light-induced dehalogenation.

The injectable grade is controlled for bacterial endotoxins per USP <85>; the limit is derived from the maximum intended parenteral dose. As an example calculation, a 1000 mg/day intravenous dose at a 5 EU/kg threshold for a 70 kg adult gives a product endotoxin limit of 0.35 EU/mg. Sub-visible particulate matter is controlled per USP <788> for small-volume injections after reconstitution. Bioburden is measured according to USP <61> and USP <62>. If terminal sterilization cannot be used because of aldehyde-related lability, aseptic filtration through a 0.22 µm filter is required; filter compatibility studies should be executed with the formulated solution rather than the dry API because dimethylacetamide or dimethyl sulfoxide wetting can extract filter components that are not observed in dry product.

Table 1 lists representative release controls for the two grades. These are model acceptance criteria for early-phase development; commercial limits are set from process validation and stability data.

Downstream filling of oral granules into sachets or capsules is performed under 25–35% RH. Granules are sized through a 1.0 mm screen and mixed with extragranular disintegrant before encapsulation. If sachet filling is used, seal integrity is tested according to ASTM F88 or an equivalent method. The aldehyde-containing granule can react with oxygen, and packaging with a desiccant and an oxygen scavenger is appropriate if long-term stability data show oxidative degradation.

If Direct Compression Is Selected, Particle Size and Batch-to-Batch Variability Require Tight Control

Direct compression is preferred over wet granulation only when the incoming lot has a D₉₀ below 75 µm and loss on drying below 0.5%. Batch-to-batch particle size variability from recrystallization can shift the angle of repose from 35° to 50° and alter die filling. When direct compression is not feasible, roller compaction is used: the API is densified with microcrystalline cellulose and crospovidone, then milled to granules. Roll pressure of 4–8 MPa and roll gap 1.0–2.5 mm are typical screening ranges; compacts with high elastic recovery may produce weak ribbons if roll speed is too high. Dry granulation avoids the aldehyde hydration risk of aqueous wet granulation and is therefore the preferred route for stabilizing labile formulations.

For fluid-bed granulation, a binder solution containing hydroxypropyl cellulose in ethanol/water 85:15 v/v can reduce aldehyde hydration. Screening parameters include inlet air temperature 50–60 °C, product temperature 30–35 °C, spray rate 5–10 g/min, and final moisture ≤ 1.5%. These values are not release limits and must be correlated with content uniformity, related substances, and dissolution data.

Compared with 2-amino-5-bromobenzaldehyde and 2-aminobenzaldehyde, the 3,5-dibromo substitution raises molecular weight to 278.93 g/mol and increases calculated lipophilicity. The second bromine at position 3 further reduces ring electron density and alters the reactivity of the aldehyde toward nucleophiles; published rate constants for this exact derivative are limited. Table 2 summarizes the structural and formulation-relevant differences.

The dibromo derivative is not interchangeable with mono-brominated or non-halogenated amino benzaldehydes in a validated formulation. Its higher lipophilicity may reduce dissolution in pH 6.8 phosphate buffer; if dissolution failure is observed, a surfactant such as sodium lauryl sulfate at 0.1–0.5% w/v can be evaluated, provided aldehyde-surfactant adducts are not detected by HPLC. Storage in amber glass under nitrogen at 15–25 °C is recommended, with desiccant for solid oral grade and endotoxin-free containers for injectable grade. Avoid direct sunlight and open handling above 60% RH.